5:05 PM
 | 
Aug 06, 2013
 |  BC Extra  |  Company News

FDA panel unanimously backs Bayer's riociguat

In a pair of 11-0 votes, FDA's Cardiovascular and Renal Drugs Advisory Committee recommended approval of Adempas riociguat from Bayer AG (Xetra:BAYN) to treat pulmonary hypertension (PAH) and to treat chronic thromboembolic pulmonary hypertension...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >